| Name | Title | Contact Details |
|---|
Our Vision is to make healthcare accessible to patients, without compromise, by delivering the highest quality, fastest, cost effective and portable detection systems that bring the patient and caregiver closer together.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The companys revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Propeller is the leading digital platform for respiratory health management.Through sensors, mobile apps and services, Propeller helps reduce the cost of care while delivering better quality of life for individuals with chronic respiratory disease. Backed by Safeguard Scientifics, Social Capital, California HealthCare Foundation and other investors, Propeller Health is now working with organizations like Dignity Health, Wyckoff Heights Medical Center, Amerigroup Florida and the City of Louisville. Company recognition includes TEDMED Innovation Showcase, White House Champion of Change and Bluetooth Breakthrough Product awards. The system has been featured in The Economist, Washington Post, Fast Company, Wired and Scientific American.
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.
4Front (CSE: FFNT) (OTCQX: FFNTF) is a national multi-state cannabis operator and retailer, with a market advantage in mass-produced, low-cost quality branded cannabis products. 4Front manufactures and distributes a portfolio of over 25 cannabis brands including Marmas, Crystal Clear, Funky Monkey, Pebbles, and the Pure Ratios wellness collection, distributed through retail outlets and their chain of strategically positioned Mission branded dispensaries. Headquartered in Phoenix, Arizona, 4Front has operations in Illinois, Massachusetts, California, Michigan and Washington state. From plant genetics to the cannabis retail experience, 4Front`s team applies expertise across the entire cannabis value chain.